The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Melnikov M.V.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency;
Pirogov Russian National Research Medical University;
National Research Center Institute of Immunology of the Federal Medical Biological Agency

Sviridova A.A.

Federal Center of Brain research and Neurotechnologies of the Federal Medical Biological Agency of Russia

Solodova T.V.

Federal Center of Brain research and Neurotechnology;
Pirogov Russian National Research Medical University

Lopatina A.V.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Pashenkov M.V.

National Research Center Institute of Immunology of the Federal Medical Biological Agency of Russia

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Blockade of D1-like dopaminergic receptors suppresses Th17-cell function in multiple sclerosis

Authors:

Melnikov M.V., Sviridova A.A., Solodova T.V., Lopatina A.V., Pashenkov M.V., Boyko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2): 82‑89

DOI: 10.17116/jnevro202112107282

Read: 3179 times

Download PDF (RU)
Contact the author
Table of contents

BLOCKADE OF D1-LIKE DOPAMINERGIC RECEPTORS SUPPRESSES TH17-CELL FUNCTION IN MULTIPLE SCLEROSIS
BLOCKADE OF D1-LIKE DOPAMINERGIC RECEPTORS SUPPRESSES TH17-CELL FUNCTION IN MULTIPLE SCLEROSIS

To cite this article:

Melnikov MV, Sviridova AA, Solodova TV, Lopatina AV, Pashenkov MV, Boyko AN. Blockade of D1-like dopaminergic receptors suppresses Th17-cell function in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2):82‑89. (In Russ.)
https://doi.org/10.17116/jnevro202112107282

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
Epidemiology of multiple scle­rosis in the city of Novo­sibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Abstract:

OBJECTIVE

To investigate the direct effect of D1-like dopaminergic receptors antagonist on Th17-cells function in multiple sclerosis (MS) in vitro.

MATERIAL AND METHODS

Forty-one relapsing-remitting MS patients and twenty-five healthy subjects were examined. The functional activity of Th17-cells was assessed by the ability to produce IL-17 and IFN-γ by peripheral blood mononuclear cells (PBMCs) and CD4+ T cells, stimulated with microbeads coated with anti-CD3/anti-CD28-antibodies. To study the involvement of D1-like dopaminergic receptors in modulation of Th17-cell function, the samples of PBMCs or CD4+ T-cells were cultured in the presence of dopamine and/or specific D1-like dopaminergic receptors antagonist (SCH23390). Cytokine levels in cell culture supernatants were measured by ELISA.

RESULTS

The production of IL-17 and IFN-γ by stimulated PBMCs were higher in MS patients during relapse than in MS patients during clinical remission or in healthy subjects. The production of cytokines by stimulated PBMCs or CD4+ T-cells in MS patients during clinical remission and healthy subjects was comparable. Dopamine reduced the production of cytokines by PBMCs and CD4+ T-cells in all groups. Blockade of D1-like dopaminergic receptors did not affect the dopamine-mediated cytokine suppression in MS patients and healthy subjects. Blockade of D1-like dopaminergic receptors directly suppressed cytokine production by PBMCs and CD4+ T-cells in MS patients and healthy subjects.

CONCLUSIONS

Dopamine and blockade of D1-like dopaminergic receptors have an inhibitory effect on Th17-cell function in MS. The activation of D2-like dopaminergic receptors could mediate the inhibitory effect of dopamine on Th17-cells.

Keywords:

dopamine
D1-like dopaminergic receptors
Th17-cells
multiple sclerosis

Authors:

Melnikov M.V.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency;
Pirogov Russian National Research Medical University;
National Research Center Institute of Immunology of the Federal Medical Biological Agency

Sviridova A.A.

Federal Center of Brain research and Neurotechnologies of the Federal Medical Biological Agency of Russia

Solodova T.V.

Federal Center of Brain research and Neurotechnology;
Pirogov Russian National Research Medical University

Lopatina A.V.

Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Pashenkov M.V.

National Research Center Institute of Immunology of the Federal Medical Biological Agency of Russia

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Received:

21.05.2021

Accepted:

26.05.2021

Close metadata

References:

  1. Levite M, Marino F, Cosentino M. Dopamine, T cells and multiple sclerosis (MS). J Neural Transm (Vienna). 2017;124(5):525-542.  https://doi.org/10.1007/s00702-016-1640-4
  2. Kawano M, Takagi R, Saika K, et al. Dopamine regulates cytokine secretion during innate and adaptive immune responses. Int Immunol. 2018;30(12):591-606.  https://doi.org/10.1093/intimm/dxy057
  3. Melnikov M, Rogovskii V, Boyko A, Pashenkov M. Dopaminergic Therapeutics in Multiple Sclerosis: Focus on Th17-Cell Functions. J Neuroimmune Pharmacol. 2020;15(1):37-47.  https://doi.org/10.1007/s11481-019-09852-3
  4. Nakano K, Higashi T, Hashimoto K, et al. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun. 2008;373(2):286-291.  https://doi.org/10.1016/j.bbrc.2008.06.012
  5. Prado C, Contreras F, González H, et al. Stimulation of dopamine receptor D5 expressed on DCs potentiates Th17-mediated immunity. J Immunol. 2012;188(7):3062-3070. https://doi.org/10.4049/jimmunol.1103096
  6. Prado C, Gaiazzi M, González H, et al. Dopaminergic Stimulation of Myeloid Antigen-Presenting Cells Attenuates Signal Transducer and Activator of Transcription 3-Activation Favouring the Development of Experimental Autoimmune Encephalomyelitis. Front Immunol. 2018;9:571.  https://doi.org/10.3389/fimmu.2018.00571
  7. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.  https://doi.org/10.1016/S1474-4422(17)30470-2
  8. Kurtzke, J.F. Rating neurologyc impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452 
  9. Boyko A, Melnikov M. Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies. Brain Sci. 2020;10(5):305.  https://doi.org/10.3390/brainsci10050305
  10. Moser T, Akgün K, Proschmann U, et al. The role of TH17 cells in multiple sclerosis: Therapeutic implications. Autoimmun Rev. 2020;19(10):102647. https://doi.org/10.1016/j.autrev.2020.102647
  11. Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics. 2013;10(3):459-472.  https://doi.org/10.1007/s13311-013-0187-4
  12. Kozhieva MKh, Melnikov MV, Rogovsky VS. et al. Human gut microbiota and multiple sclerosis. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(10-2):11-19. (In Russ.). https://doi.org/10.17116/jnevro201711710211-19
  13. Boziki MK, Kesidou E, Theotokis P, et al. Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know. Brain Sci. 2020;10(4):234.  https://doi.org/10.3390/brainsci10040234
  14. Cosentino M, Marino F. Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks? J Neuroimmune Pharmacol. 2013;8(1):163-179.  https://doi.org/10.1007/s11481-012-9410-z
  15. Marino F, Cosentino M. Multiple sclerosis: Repurposing dopaminergic drugs for MS — the evidence mounts. Nat Rev Neurol. 2016;12(4):191-192.  https://doi.org/10.1038/nrneurol.2016.33
  16. Melnikov M, Sviridova A, Rogovskii V, et al. Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy. Mult Scler Relat Disord. 2021;51:102888. https://doi.org/10.1016/j.msard.2021.102888
  17. Matt SM, Gaskill PJ. Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease. J Neuroimmune Pharmacol. 2020;15(1):114-164.  https://doi.org/10.1007/s11481-019-09851-4
  18. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev. 2000;24(1):125-132.  https://doi.org/10.1016/s0149-7634(99)00063-9
  19. Melnikov MV, Paschenkov MV, Boyko AN. Dendritic cells in multiple sclerosis. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(2 Vyp 2):22-30. (In Russ). https://doi.org/10.17116/jnevro20171172222-30
  20. Huang Y, Chen CC, Wang TT, et al. Dopamine receptors modulate T lymphocytes via inhibition of cAMP-CREB signaling pathway. Neuro Endocrinol Lett. 2016;37(7):491-500. 
  21. Dijkstra CD, van der Voort ER, De Groot CJ, et al. Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology. 1994;19(2):135-142.  https://doi.org/10.1016/0306-4530(94)90003-5
  22. Bissay V, De Klippel N, Herroelen L, et al. Bromocriptine therapy in multiple sclerosis: an open label pilot study. Clin Neuropharmacol. 1994;17(5):473-476.  https://doi.org/10.1097/00002826-199410000-00011
  23. Cosentino M, Zaffaroni M, Ferrari M, et al. Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis. J Neuroimmunol. 2005;162(1-2):112-121.  https://doi.org/10.1016/j.jneuroim.2005.01.019
  24. Zaffaroni M, Marino F, Bombelli R, et al. Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. Exp Neurol. 2008;214(2):315-321.  https://doi.org/10.1016/j.expneurol.2008.08.015
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.